Health care professionals and patients can access the approval letters and latest prescribing information by searching for canagliflozin at: Drugs@FDA This information is an update to the FDA ...

The pharmacokinetics of this compound are similar in study subjects with diabetes and in those without. Age, gender, body weight, race, administration with food, or mild renal impairment do not ...

The group led by Graduate School of Medicine Associate Professor Katsuhito Mori focused on the SGLT2 inhibitor canagliflozin and its effects on the kidney. Using BOLD (blood oxygenation level ...